Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors.
In this instalment, Dominic Tyer is joined by Kinomica CEO Jane Theaker, BioCity investment director Claire Brown, Redx Pharma CEO Lisa Anson and Dr Kath Mackay, managing director at Bruntwood SciTech – Alderley Park.
Claire and Jane looked at how Kinomica secured £3.9 million in funding from investors, including Alderley Park Ventures and BioCity. The funding marked a major milestone for KScan, its next-generation biomarker and molecular diagnostics platform for treating cancer patients and other conditions.
Redx Pharma’s Lisa Anson talked about the company’s multi-million global licensing deal with pharma giant AstraZeneca, which will further develop and commercialise its treatment for sufferers of fibrotic diseases, and its other recent fundraising milestones.
The episode also heard Dr Kath Mackay discuss Alderley Park’s business support programme the Alderley Park Accelerator, which mentors companies through the investment process, and showcase why creating connections is so important.
Alderley Park, a development by Bruntwood SciTech, is the UK’s largest single-site life science campus and offers bioscience facilities for R&D-focussed life science companies at every stage of their lifecycle, from start-up to global corporate.
Episode two of its podcast looked at why university connections are vital for a life science and tech cluster like Alderley Park and how the campus works to inspire the next generation of scientists.
Meanwhile, the first episode focused on the challenges of rapidly building capacity for thousands of COVID tests at the Alderley Park Lighthouse Lab.
Episode three of the Alderley Park Discovery Podcast is available in the player below, where you can listen to it, download it to your computer or find – and subscribe to the series, and other pharmaphorum podcasts – in iTunes, Spotify, acast, Stitcher and Podbean.